Residual effects of low dose of suvorexant, zolpidem, and ramelteon in healthy elderly subjects: A randomized double-blind study.
hypnotics
residual effects
sleep
suvorexant
zolpidem
Journal
Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
27
04
2022
received:
03
12
2021
accepted:
01
05
2022
pubmed:
25
6
2022
medline:
30
9
2022
entrez:
24
6
2022
Statut:
ppublish
Résumé
Current hypnotic agents have next-day residual effects. The new orexin antagonist, suvorexant, has little muscle relaxation effect on the physical and cognitive function in the following morning and daytime. In this study, the effects of suvorexant, zolpidem, ramelteon and placebo in elderly subjects were evaluated. Six men and eight women aged 63-75 years received a single tablet and lights were then turned off. Subjects were instructed to sleep from 23:00-6:00 with an interruption from 4:00-4:30 for evaluations. Suvorexant 10 mg, zolpidem 5 mg, ramelteon 4 mg or placebo was administered single time in a randomized, double-blind and crossover design with a one-week drug holiday in between each drug. Measures of objective parameters and subjective ratings were obtained every 2 h from 4:00 to 16:00. No subjects showed serious side effects from physical observations and vital sign checks before and after hypnotics were taken. During the first sleep period, the REM sleep time with suvorexant was especially longer than that with zolpidem. During the second sleep period, suvorexant had shorter sleep latency and longer stage2 sleep time than ramelteon and zolpidem, respectively. During the whole entire sleep, the REM sleep time with suvorexant was longer than zolpidem and placebo. For the body sway test with closed eye, the main effects of the medicines and zolpidem were significantly better than suvorexant and ramelteon. The changes of physical and cognitive functions in healthy elderly after taking hypnotics were not remarkable. Therefore, these three hypnotics maybe appropriate for the elderly people with insomnia for single-time low dose administration.
Identifiants
pubmed: 35748642
doi: 10.1002/npr2.12262
pmc: PMC9515713
doi:
Substances chimiques
Azepines
0
Hypnotics and Sedatives
0
Indenes
0
Orexins
0
Triazoles
0
suvorexant
081L192FO9
Zolpidem
7K383OQI23
ramelteon
901AS54I69
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
288-298Informations de copyright
© 2022 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
Références
Ann N Y Acad Sci. 2010 Jul;1200:149-61
pubmed: 20633143
Lancet Neurol. 2014 May;13(5):461-71
pubmed: 24680372
Biol Pharm Bull. 2020;43(6):925-931
pubmed: 32475914
Shinrigaku Kenkyu. 1986 Jun;57(2):87-91
pubmed: 3784166
Br J Clin Pharmacol. 2004 Dec;58(7):S720-40; discussion S741-3
pubmed: 15595961
Sleep Biol Rhythms. 2017;15(3):235-241
pubmed: 28680342
PLoS One. 2020 Sep 11;15(9):e0238723
pubmed: 32916693
Sleep Med Rev. 2010 Aug;14(4):259-67
pubmed: 20171127
Hum Psychopharmacol. 2012 May;27(3):270-6
pubmed: 22350925
Sleep Med. 2015 Nov;16(11):1395-1402
pubmed: 26498242
Psychophysiology. 1973 Jul;10(4):431-6
pubmed: 4719486
Drugs Aging. 2008;25(6):521-9
pubmed: 18540690
Neuropharmacology. 2005 Feb;48(2):301-10
pubmed: 15695169
Front Neurosci. 2013 Dec 24;7:254
pubmed: 24399926
Arch Gen Psychiatry. 2006 Oct;63(10):1149-57
pubmed: 17015817
J Clin Sleep Med. 2007 Mar 15;3(2):121-31
pubmed: 17557422
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24353-24358
pubmed: 31712421
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
Geriatr Gerontol Int. 2016 Sep;16(9):983-1001
pubmed: 27594406
Sleep. 1991 Aug;14(4):331-8
pubmed: 1947597
Nat Med. 2007 Feb;13(2):150-5
pubmed: 17259994
J Clin Psychopharmacol. 2002 Dec;22(6):576-83
pubmed: 12454557
Curr Psychiatry Rep. 2016 Oct;18(10):89
pubmed: 27549604
Sleep. 2000 Feb 1;23(1):41-7
pubmed: 10678464
Sleep Med. 2007 Nov;8(7-8):723-32
pubmed: 17512790
Psychiatry Res. 2000 Dec 27;97(2-3):165-72
pubmed: 11166088
Neuropsychopharmacol Rep. 2022 Sep;42(3):288-298
pubmed: 35748642
Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1321-7
pubmed: 23097414
Neurotherapeutics. 2012 Oct;9(4):728-38
pubmed: 22976558
J Gerontol A Biol Sci Med Sci. 2005 May;60(5):622-6
pubmed: 15972615
J Epidemiol. 2000 Mar;10(2):79-86
pubmed: 10778031
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:509-533
pubmed: 27860547
Artif Intell Med. 2005 Mar;33(3):199-207
pubmed: 15811785
Biol Psychiatry. 2016 Jan 15;79(2):136-48
pubmed: 25526970
Sleep Med. 2006 Jun;7(4):312-8
pubmed: 16709464
Eur J Clin Pharmacol. 2014 Jul;70(7):873-80
pubmed: 24810612
BMC Neurosci. 2014 Sep 22;15:109
pubmed: 25242351
Clin Ther. 2006 Oct;28(10):1540-55
pubmed: 17157111
Eur Neuropsychopharmacol. 2016 Oct;26(10):1649-56
pubmed: 27554636
Clin Ther. 1993 Jan-Feb;15(1):127-36
pubmed: 8458042
Eur J Clin Pharmacol. 2003 Jul;59(3):179-88
pubmed: 12756510
Sleep Med. 2014 Apr;15(4):385-92
pubmed: 24656909
J Gerontol. 1990 Nov;45(6):M192-7
pubmed: 2229941
Drugs Aging. 2018 Sep;35(9):791-817
pubmed: 30058034
Prim Care Companion J Clin Psychiatry. 1999 Aug;1(4):114-120
pubmed: 15014684
Br J Clin Pharmacol. 2009 Feb;67(2):180-90
pubmed: 19094161
Yakugaku Zasshi. 2020;140(8):1041-1049
pubmed: 32741862
Clin Ther. 2016 Nov;38(11):2340-2372
pubmed: 27751669
Sleep Med. 2010 May;11(5):462-9
pubmed: 20363670
Neurosci Res. 2007 Nov;59(3):309-13
pubmed: 17825448
PLoS One. 2015 Jun 10;10(6):e0129366
pubmed: 26061231